I discuss the impact that the U.S. Drug Enforcement Administration’s potential reclassification of cannabis would affect Georgia’s medical cannabis industry in his article published by Cannabis Industry Journal.
In particular, I consider three key areas of impact:
(1) How Georgia medical cannabis distributors would operate within this new regulatory framework;
(2) How this change would affect registered Georgia patients who are either currently purchasing medical cannabis or are planning to do so; and
(3) Whether this reclassification would cause big pharmaceutical companies to enter Georgia’s medical cannabis market, and if so, how.
/Passle/5fe0c4f453548a10fc881e09/SearchServiceImages/2024-12-13-15-38-26-547-675c54f2e06e54924eccb07e.jpg)
/Passle/5fe0c4f453548a10fc881e09/SearchServiceImages/2024-12-16-17-38-15-333-67606587044a44825e002930.jpg)
/Passle/5fe0c4f453548a10fc881e09/SearchServiceImages/2024-12-10-15-07-12-595-675859207e4ada72eef78335.jpg)